Protalix BioTherapeutics (PLX) Cash & Current Investments (2010 - 2026)

Protalix BioTherapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 68.93% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $10.8 million (down 68.93% YoY), while the FY2025 annual figure was $16.3 million, up 8.13% from the prior year.
• Cash & Current Investments was $10.8 million for Q1 2026 at Protalix BioTherapeutics, down from $16.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $48.5 million in Q1 2024 to a low of $10.8 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $31.3 million across 5 years, with a median of $32.9 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Cash & Current Investments jumped 100.9% in 2023, then sank 68.93% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $22.2 million in 2022, then surged by 100.9% to $44.6 million in 2023, then sank by 66.18% to $15.1 million in 2024, then increased by 8.13% to $16.3 million in 2025, then tumbled by 33.76% to $10.8 million in 2026.
• The last three Cash & Current Investments figures came in at $10.8 million (Q1 2026), $16.3 million (Q4 2025), and $29.4 million (Q3 2025), per Business Quant data.